When Insurance Keeps the Coupon: The Growing Impact of Copay Accumulator Programs

Larry Gruber, a 45‑year‑old fitness coach from Wilton Manors, Florida, has lived with psoriatic arthritis for over a decade. His lifeline? Enbrel, a biologic that costs more than $7,700 a month. For 16 years he relied on a coupon card sent by Amgen, the drug’s maker, to meet his insurance’s deductible and out‑of‑pocket maximum.

Every year the coupon, worth a few thousand dollars, would apply toward his cost‑sharing. By February he would have hit his annual maximum, and the rest of the year the medication would be covered at $0. It was a system that felt almost generous – until his new insurer, Oscar Health, decided to change the rules.

Oscar Health’s plan included a “copay accumulator” clause. In plain English, the insurer refused to count the manufacturer’s coupon toward Larry’s out‑of‑pocket tally. That meant Larry had to keep paying the full price of Enbrel until he spent $10,600 on his own – a sum that quickly ate into savings earmarked for a down‑payment on a house.

“The real insult is that they’re taking money that’s supposed to help you,” Larry told reporters, his voice cracking with frustration. “I feel desperate, pressed against a wall, and squeezed.”

Oscar Health, like many commercial insurers, argues that copay accumulators are a tool to curb rising prescription costs and keep premiums down. Matt Choffin, the company’s Florida market president, declined to comment on Larry’s specific case but defended the practice as a necessary cost‑control measure.

Drug manufacturers push back, saying these accumulator programs effectively sabotage the very assistance they provide. “It’s a double‑dip,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute. “Insurers keep the coupon money and still collect the patient’s contribution. Patients get the short end of the stick.”

The controversy isn’t limited to Oscar Health. Over the past decade, a growing number of insurers have adopted similar policies, especially for high‑priced specialty drugs used to treat autoimmune diseases, multiple sclerosis, diabetes, HIV and cancer. According to Avalere Health, the trend reflects an industry‑wide scramble to curb drug spend.

Patients most vulnerable to these programs are often heavy users of the healthcare system. Delays or interruptions in therapy can worsen conditions, leading to even higher overall costs—a point patient advocates stress repeatedly.

Regulation adds another layer of complexity. Medicare and Medicaid explicitly ban copay assistance because federal anti‑kickback rules forbid manufacturers from influencing patient choices. High‑deductible plans paired with health‑savings accounts also face IRS restrictions. But for the roughly 40 % of ACA marketplace plans that still employ accumulators, oversight rests mainly with state regulators.

A recent review by the nonprofit AIDS Institute found that 10 of Florida’s 16 marketplace insurers use copay accumulator programs. For someone like Larry, who has no generic alternative to Enbrel, the choice is stark: pay out‑of‑pocket or risk disease progression.

In the end, the debate circles back to a simple question: should insurers be allowed to keep money that was explicitly intended to ease a patient’s financial burden? As more stories like Larry’s emerge, lawmakers, advocates, and consumers alike will have to grapple with that answer.